Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pneuma Nitric Oxide is a private U.S. health and wellness company commercializing nitric oxide-based consumer products, especially topical skincare and dietary supplement offerings sold under the N1O1 brand. The business appears to be founded and led by nitric oxide researcher Dr. Nathan S. Bryan and is positioned as a commercialization vehicle for his nitric oxide science and related intellectual property. Its flagship products include a dual-chamber nitric oxide-activating serum and nitric oxide lozenges, with marketing focused on anti-aging skin care, circulation, and general wellness. External sources also describe Pneuma Nitric Oxide as the consumer products division of Bryan Therapeutics, a clinical-stage biotechnology company developing nitric oxide-based therapeutics. Overall, Pneuma Nitric Oxide is best characterized as a commercial consumer-health brand adjacent to biotech rather than a standalone drug-development company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pneuma Nitric Oxide.